Baicalin

Baicalin is a flavone glycoside compound derived from Scutellaria baicalensis (Chinese skullcap) that demonstrates potent anti-inflammatory activity through inhibition of nuclear factor-kappa B (NF-κB) signaling pathways. Research shows it significantly reduces inflammatory markers like IL-6 and myeloperoxidase in preclinical models of inflammatory bowel disease and arthritis.

Origin & History

Baicalin is a flavonoid glycoside isolated from the roots of Scutellaria baicalensis (Chinese skullcap), a plant used in traditional Chinese medicine. It belongs to the chemical class of flavone glucuronides (specifically 5,6,7-trihydroxyflavone-7-O-glucuronide) and is typically extracted from dried roots via solvent methods followed by purification.

Historical & Cultural Context

Baicalin originates from Scutellaria baicalensis roots, used in Traditional Chinese Medicine for over 2,000 years to clear heat, dry dampness, and treat inflammatory conditions like fever, dysentery, and respiratory infections. Historical TCM applications for anti-inflammatory and detoxifying purposes form the basis for modern research into arthritis and colitis.

Health Benefits

• Anti-inflammatory effects: Meta-analysis of 17 animal studies showed significant reduction in inflammatory markers IL-6 (SMD = -10.59) and MPO (SMD = -7.34) in ulcerative colitis models (preliminary evidence only)
• Arthritis management: Reduced paw thickness and inflammatory cytokines in collagen-induced arthritis models via TLR2/MYD88/NF-κB suppression (animal studies only)
• Intestinal barrier protection: Improved disease activity index (MD = -2.75) and histopathology scores (SMD = -3.91) in UC animal models (PMID: 39901089, preliminary evidence)
• Antioxidant activity: Increased SOD levels and reduced ROS via Bcl-2/Bax modulation in preclinical models (animal/in vitro evidence)
• Anti-cancer synergy: Enhanced apoptosis when combined with chemotherapy in breast cancer models (in vitro evidence only)

How It Works

Baicalin exerts its anti-inflammatory effects primarily through inhibition of the nuclear factor-kappa B (NF-κB) signaling pathway, which regulates inflammatory gene expression. The compound also modulates cyclooxygenase-2 (COX-2) and lipoxygenase enzymes, reducing production of pro-inflammatory prostaglandins and leukotrienes. Additionally, baicalin demonstrates antioxidant activity by scavenging reactive oxygen species and upregulating antioxidant enzymes like superoxide dismutase.

Scientific Research

Clinical evidence for baicalin is limited to preclinical studies, with no human trials identified. A 2024 meta-analysis of 17 animal RCTs (PMID: 39901089) demonstrated significant improvements in ulcerative colitis biomarkers, but emphasized the urgent need for human studies. Human safety data exists only for the related compound baicalein (200-600 mg/day), not baicalin itself.

Clinical Summary

Current evidence for baicalin comes primarily from preclinical animal studies, with limited human clinical data available. A meta-analysis of 17 animal studies in ulcerative colitis models showed significant reductions in IL-6 (SMD = -10.59) and myeloperoxidase (SMD = -7.34) inflammatory markers. In arthritis models, baicalin reduced paw swelling and inflammatory cytokines, though effect sizes and dosages varied across studies. Human clinical trials are needed to establish therapeutic efficacy and optimal dosing protocols.

Nutritional Profile

Baicalin is a flavonoid glycoside (flavone class) and not a food ingredient with conventional macronutrient or micronutrient content. It is a purified bioactive compound, therefore standard nutritional profiling (calories, protein, fat, carbohydrates) is not applicable in the traditional sense. Key compositional data: Molecular formula C21H18O11, molecular weight 446.36 g/mol. It is the glucuronide conjugate of baicalein, with a glucuronic acid moiety attached at the 7-position of the baicalein backbone. Primary source: Root of Scutellaria baicalensis (Chinese skullcap), where baicalin constitutes approximately 10–15% dry weight of the root, with some extracts standardized to 85–95% baicalin purity in supplement form. Typical commercial extract concentrations range from 200 mg to 500 mg per capsule dose. Bioavailability is notably limited due to poor water solubility (approximately 0.2 mg/mL in water) and extensive first-pass metabolism; oral bioavailability is estimated at less than 2–3% in its intact glycoside form. Intestinal microbiota and gut mucosal β-glucuronidase enzymes hydrolyze baicalin to its aglycone baicalein, which is more readily absorbed. Peak plasma concentration (Cmax) following oral administration in human pharmacokinetic studies is typically low (nanomolar to low micromolar range). No significant vitamin, mineral, fiber, or protein content is present as it is an isolated phytochemical compound, not a whole food.

Preparation & Dosage

No human dosage data exists for baicalin. Animal studies suggest 60-150 mg/kg for ulcerative colitis models over 10-14 days. Related compound baicalein has been tested at 200-600 mg/day in humans with good tolerability. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Baicalein, Curcumin, Quercetin, Green Tea Extract, Boswellia

Safety & Interactions

Baicalin appears generally well-tolerated in animal studies, though comprehensive human safety data is lacking. The compound may interact with cytochrome P450 enzymes, particularly CYP2C9 and CYP3A4, potentially affecting metabolism of certain medications including warfarin and some statins. Theoretical concerns exist regarding additive effects with anticoagulant medications due to potential bleeding risk. Safety during pregnancy and lactation has not been established, and use should be avoided in these populations.